CA2755301C - Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy - Google Patents

Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy Download PDF

Info

Publication number
CA2755301C
CA2755301C CA2755301A CA2755301A CA2755301C CA 2755301 C CA2755301 C CA 2755301C CA 2755301 A CA2755301 A CA 2755301A CA 2755301 A CA2755301 A CA 2755301A CA 2755301 C CA2755301 C CA 2755301C
Authority
CA
Canada
Prior art keywords
biomarkers
expression
biomarker
extent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2755301A
Other languages
English (en)
French (fr)
Other versions
CA2755301A1 (en
Inventor
Robert T. Streeper
Elzbieta Izbicka
Sung H. Baek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Prevention and Cure Ltd
Original Assignee
Cancer Prevention and Cure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/403,369 external-priority patent/US8541183B2/en
Application filed by Cancer Prevention and Cure Ltd filed Critical Cancer Prevention and Cure Ltd
Priority to CA3024643A priority Critical patent/CA3024643C/en
Publication of CA2755301A1 publication Critical patent/CA2755301A1/en
Application granted granted Critical
Publication of CA2755301C publication Critical patent/CA2755301C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2755301A 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy Active CA2755301C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3024643A CA3024643C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/403,369 2009-03-12
US12/403,369 US8541183B2 (en) 2007-09-11 2009-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US23719809P 2009-08-26 2009-08-26
US61/237,198 2009-08-26
PCT/US2010/027243 WO2010105235A2 (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3024643A Division CA3024643C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Publications (2)

Publication Number Publication Date
CA2755301A1 CA2755301A1 (en) 2010-09-16
CA2755301C true CA2755301C (en) 2019-01-08

Family

ID=42729154

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2755301A Active CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
CA3024643A Active CA3024643C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3024643A Active CA3024643C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Country Status (10)

Country Link
US (1) US11474104B2 (https=)
EP (4) EP3444359A1 (https=)
JP (7) JP2012520469A (https=)
KR (2) KR102061441B1 (https=)
CN (4) CN108181457B (https=)
AU (3) AU2010223911A1 (https=)
CA (2) CA2755301C (https=)
ES (1) ES2703714T3 (https=)
PL (1) PL3257953T3 (https=)
WO (1) WO2010105235A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
AU2012249288C1 (en) * 2011-04-29 2017-12-21 Lung Cancer Proteomics Llc Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
KR102087373B1 (ko) * 2015-09-11 2020-03-10 주식회사 압타머사이언스 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
CN108473529B (zh) * 2015-11-10 2023-04-18 伦斯勒中心转化研究公司 检测和治疗肺高压的方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112501140B (zh) * 2020-12-16 2022-03-18 熊猫乳品集团股份有限公司 一种生物活性多肽yfgsgfaapffivrhqllkk及其制备方法和应用
TWI796010B (zh) * 2021-11-23 2023-03-11 國立高雄大學 基質金屬蛋白酶-1胜肽拓印導電聚合物及其用途
CN117907508A (zh) * 2023-12-19 2024-04-19 查理高特(青岛)健康科技有限公司 基于代谢组学的高尿酸血症及尿酸性肾病的风险预测系统

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280930C (en) 1997-02-12 2010-04-06 The Regents Of The University Of Michigan Protein markers for lung cancer and use thereof
US20070092917A1 (en) 1998-05-01 2007-04-26 Isabelle Guyon Biomarkers for screening, predicting, and monitoring prostate disease
EP1156823B1 (en) 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
IL144559A0 (en) 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
FI990888A0 (fi) * 1999-04-20 1999-04-20 Medix Biochemica Ab Oy Menetelmä ja testikittejä respiratorisen alueen tulehduksen läsnäolon ja vaikeusasteen arvioimiseksi
BR0010068A (pt) * 1999-04-26 2002-12-17 Surromed Inc Sistema de identificação do marcador fenotìpico e biológico
WO2002004600A2 (en) * 2000-07-12 2002-01-17 Smithkline Beecham Corporation Novel compounds
KR20030094281A (ko) * 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
JP2004532640A (ja) 2001-06-05 2004-10-28 オークランド ユニサーヴィスィズ リミテッド 肺機能および障害の評価のための方法および組成物
US20030134339A1 (en) 2002-01-14 2003-07-17 Thomas Brown Proteomics based method for toxicology testing
US20060088537A1 (en) 2002-04-11 2006-04-27 Terrett Jonathan A Protein involved in cancer
JP2006509186A (ja) 2002-05-10 2006-03-16 イースタン バージニア メディカル スクール 前立腺癌バイオマーカー
WO2003101283A2 (en) * 2002-06-04 2003-12-11 Incyte Corporation Diagnostics markers for lung cancer
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
CN1854313B (zh) * 2002-09-30 2010-10-20 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
WO2004073623A2 (en) * 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
JP2007537984A (ja) * 2003-03-04 2007-12-27 ワイス 喘息または他のアレルギー性もしくは炎症性疾患の診断および治療のための組成物および方法
CN101265254A (zh) * 2003-03-27 2008-09-17 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
JP2005044330A (ja) 2003-07-24 2005-02-17 Univ Of California San Diego 弱仮説生成装置及び方法、学習装置及び方法、検出装置及び方法、表情学習装置及び方法、表情認識装置及び方法、並びにロボット装置
US7700573B2 (en) 2004-03-23 2010-04-20 Oncotherapy Science, Inc. Method for diagnosing non-small lung cancer
US20090204334A1 (en) 2004-03-30 2009-08-13 Eastern Virginia Medical School Lung cancer biomarkers
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
EP1805513A4 (en) * 2004-10-20 2009-06-10 Onco Detectors International L MIGRATION HEMMFAKTORIM SERUM AS TUMORMARKER FOR PROSTATE, BLADDER, BREAST, OVARIAL, KIDNEY AND LUNG CARCINOMA
WO2006045318A2 (en) * 2004-10-27 2006-05-04 Aarhus Universitet Diagnosis and treatment of immune-related diseases
CA2589782A1 (en) 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
CN1300580C (zh) 2004-12-31 2007-02-14 中国人民解放军第306医院 检测肝癌血清特征蛋白的质谱模型及其制备方法和应用
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
WO2006124451A2 (en) * 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
US20070099239A1 (en) 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP2311985A1 (en) * 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JPWO2007026773A1 (ja) 2005-08-31 2009-03-12 学校法人 久留米大学 医用診断処理装置
US7955837B2 (en) 2005-10-29 2011-06-07 Bayer Technology Services Gmbh Process for determining one or more analytes in samples of biological origin having complex composition, and use thereof
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
KR100760518B1 (ko) 2006-07-18 2007-09-20 삼성정밀공업 주식회사 가구용 도어의 닫힘 충격 완충 장치
US7840505B2 (en) 2006-11-02 2010-11-23 George Mason Intellectual Properties, Inc. Classification tool
EP2087140A2 (en) * 2006-11-13 2009-08-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
US8343491B2 (en) * 2006-12-18 2013-01-01 The Johns Hopkins University Anti-HIMF antibodies to treat lung diseases
JP5085927B2 (ja) 2006-12-21 2012-11-28 ウィンテックポリマー株式会社 難燃性樹脂組成物
CA2678626A1 (en) * 2007-02-28 2008-09-04 Novimmune S.A. Anti-ip-10 antibodies and methods of use thereof
JP2010523979A (ja) 2007-04-05 2010-07-15 オーレオン ラボラトリーズ， インコーポレイテッド 医学的状態の処置、診断および予測のためのシステムおよび方法
EP2515116A1 (en) 2007-05-18 2012-10-24 Duke University Serum biomarkers for the early detection of lung cancer
EP2156187A4 (en) 2007-06-15 2010-07-21 Biosite Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND / OR FORECASTING EGG CANCER AND LUNG CANCER
US7888051B2 (en) * 2007-09-11 2011-02-15 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
KR20160096213A (ko) 2007-09-11 2016-08-12 캔서 프리벤션 앤 큐어, 리미티드 인간 폐조직 병변의 지표가 되는 인간 혈청 내 단백질의 동정
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
JP5159242B2 (ja) 2007-10-18 2013-03-06 キヤノン株式会社 診断支援装置、診断支援装置の制御方法、およびそのプログラム
CN101896817A (zh) 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
CN102037355A (zh) 2008-03-04 2011-04-27 里奇诊断学股份有限公司 基于多重生物标记物板块诊断和监测抑郁症
CN101587125B (zh) 2008-05-21 2013-07-24 林标扬 高表达癌症标记物和低表达组织器官标记物组合试剂盒
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN104198709A (zh) 2008-09-09 2014-12-10 私募蛋白质体公司 肺癌生物标记及其用途
CN101988059B (zh) 2009-07-30 2014-04-02 江苏命码生物科技有限公司 胃癌检测标记物及其检测试剂盒和生物芯片
KR20140024860A (ko) 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트
AU2012249288C1 (en) 2011-04-29 2017-12-21 Lung Cancer Proteomics Llc Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2015066564A1 (en) 2013-10-31 2015-05-07 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2015138769A1 (en) 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer

Also Published As

Publication number Publication date
CA2755301A1 (en) 2010-09-16
JP2018072348A (ja) 2018-05-10
EP2406401A2 (en) 2012-01-18
EP2857522A3 (en) 2015-10-14
WO2010105235A2 (en) 2010-09-16
US11474104B2 (en) 2022-10-18
PL3257953T3 (pl) 2019-05-31
AU2016228188B2 (en) 2018-01-04
JP2016006426A (ja) 2016-01-14
JP2019158890A (ja) 2019-09-19
CN108181457B (zh) 2021-03-30
EP3257953A1 (en) 2017-12-20
CN113189342A (zh) 2021-07-30
CN102405296A (zh) 2012-04-04
ES2703714T3 (es) 2019-03-12
KR101900016B1 (ko) 2018-09-20
EP2857522A2 (en) 2015-04-08
CN104535765A (zh) 2015-04-22
JP2022000650A (ja) 2022-01-04
JP2012520469A (ja) 2012-09-06
CN113189342B (zh) 2024-12-03
WO2010105235A3 (en) 2011-02-24
AU2016228188A1 (en) 2016-09-29
JP2024024128A (ja) 2024-02-21
AU2018202110A1 (en) 2018-04-19
AU2018202110B2 (en) 2020-09-03
CA3024643C (en) 2021-08-03
JP6250600B2 (ja) 2017-12-20
EP2406401A4 (en) 2013-01-09
JP6774925B2 (ja) 2020-10-28
KR20180104190A (ko) 2018-09-19
EP3444359A1 (en) 2019-02-20
CA3024643A1 (en) 2010-09-16
EP3257953B1 (en) 2018-09-26
KR102061441B1 (ko) 2019-12-31
AU2010223911A1 (en) 2011-10-06
US20180356423A1 (en) 2018-12-13
CN108181457A (zh) 2018-06-19
KR20120010229A (ko) 2012-02-02
JP2025114736A (ja) 2025-08-05

Similar Documents

Publication Publication Date Title
AU2018202110B2 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender- based disease identification, assessment, prevention and therapy
US9933429B2 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US7888051B2 (en) Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
EP2195645B1 (en) Method for aiding in the diagnosis and therapy of asthma and lung cancer
EP2201363A2 (en) Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
HK40058647A (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
HK40058647B (zh) 监定、评估、预防以及治疗肺疾病的方法及试剂盒
Kullmann et al. Differential Cytokine Pattern in the Exhaled Breath of Patients with Lung Cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150312

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240911

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240911

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240911

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250228

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250228

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260310